CEO & Founder at Thymmune Therapeutics
Stan Wang is Founder and CEO of Thymmune Therapeutics, an innovative cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engineer cells. Stan received his Ph.D. from the University of Cambridge and his M.D. from Columbia University. He was a postdoctoral fellow in cell and gene therapy with George Church at Harvard Medical School.
Thymmune Therapeutics, Inc.
CEO & Founder July 2019 - present
The Council on Strategic Risks
Non-Resident Senior Fellow July 2019 - present
The Center on Strategic Weapons: Making Biological Weapons Obsolete
Cellino Biotech, Inc.
Consultant July 2019 - December 2019
Founding Chief Scientific Officer August 2017 - June 2019
Wyss Institute for Biologically Inspired Engineering
Postdoctoral Fellow September 2016 - August 2018
George Church lab, Department of Genetics, Harvard Medical School
Visit website: https://www.stanwang.com/
See also: Thymmune Therapeutics - Biotechnology company restoring Immune Function through Thymic Cell Engineering
Stan Wang News
Thymmune Therapeutics raised $7 million in seed financing
Biospace - 02-Mar-2023
Thymmune aims at developing therapies to treat several autoimmune diseases and organ transplant toleranceRead more...